Background Randomized, controlled trials demonstrated efficacy and safety of apremilast for
moderate-to-severe plaque psoriasis and psoriatic arthritis. Objective Assess long-term …

Apremilast (Otezla®) is an orally administered, small molecule inhibitor of
phosphodiesterase 4 (PDE4). Apremilast 30 mg twice daily reduced the severity of moderate …

BACKGROUND: Many patients with moderate plaque psoriasis are undertreated despite
broadening treatment options. In the phase IV UNVEIL study, oral apremilast demonstrated …

Psoriasis is a chronic inflammatory skin disease, most commonly resulting in the occurrence
of red and silver scaly plaques. About 30% of psoriasis sufferers develop psoriatic arthritis …

Objective. Apremilast, an oral phosphodiesterase 4 inhibitor, downregulates intracellular
inflammatory mediator synthesis by elevating cyclic adenosine monophosphate levels. The …

Objective. To evaluate the efficacy and safety of apremilast, an oral phosphodiesterase 4
inhibitor, over 52 weeks in patients with active psoriatic arthritis (PsA) despite prior …

Background Patients with mild-to-moderate psoriasis may have substantial quality-of-life
impairment. Objective To evaluate apremilast 30 mg twice daily for mild-to-moderate …

Apremilast (Otezla®) is an oral phosphodiesterase 4 inhibitor indicated for the twice-daily
treatment of adults with psoriasis and psoriatic arthritis (PsA). Its use in these patient …

Background Apremilast, a small molecule specific inhibitor of phosphodiesterase 4, works
intracellularly to modulate pro-inflammatory and anti-inflammatory mediators. This phase II …

Background Apremilast, a small molecule specific inhibitor of phosphodiesterase 4, works
intracellularly to modulate pro‐inflammatory and anti‐inflammatory mediator production …